

Date: May 28, 2018

To	To
NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051	BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001
Company Code No. AUROPHARMA	Company Code No. 524804

Dear Sirs,

SUB: Press Release – Reg.

We enclose copy of the Press Release issued by the Company.

This is for your information and record

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED



B. Adi Reddy
Company Secretary

AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059
Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com

NEWS RELEASE

28th May 2018, Hyderabad, India

Aurobindo Pharma Ltd Q4 FY17-18 and FY17-18 Financial Results

Consolidated financial results

Amount in INR Cr	Q4 FY17-18	Q4 FY16-17	% Chg	FY17-18	FY16-17	% Chg
Revenue from operations	4,049.1	3,641.6	11.2	16,499.8	15,089.9	9.3
EBITDA before Forex and Other income	804.0	721.2	11.5	3,788.5	3,434.3	10.3
EBITDA %	19.9%	19.8%		23.0%	22.8%	
PBT	650.6	647.7	0.4	3,238.1	3,055.8	6.0
Net Profit after JV share, minority interest	528.5	532.5	-0.7	2,423.2	2,301.7	5.3

Post implementation of GST with effect from July 1, 2017, revenue from operations of Q2FY18, Q3FY18 and Q4FY18 are net of GST.

Key Highlights of FY18 consolidated financials

- Revenue from operations at INR 16,499.8 crore, witnessed a growth of 9.3% YoY
 - US formulation revenue stood at INR 7,442.1 Cr vs INR 6,827.2 Cr in FY17, witnessed a growth of 9.0% YoY
 - Europe formulation revenue reported a robust growth of 32.9% to INR 4,354.4 Cr
 - ARV revenue at INR 839.6 Cr vs. INR 1,185.4 Cr in FY17
 - Growth Markets revenue at INR 897.1, up 18.7% over corresponding previous period
 - API revenue at INR 2,962.2 Cr vs. INR 3,042.1 Cr in FY17
- EBITDA before forex and other income registered a growth of 10.3% YoY to INR 3,788.5 crore. EBITDA margin is at 23.0%
- Net Profit after JV share, minority interest posted a growth of 5.3% YoY to INR 2,423.2 crore
- Basic & Diluted EPS is INR 41.36 per share
- Research & Development (R&D) spend at INR 666.5 crore, 4.0% of revenues

Key Highlights of Q4FY18 consolidated financials

- Revenue from Operations at INR 4,049.1 Cr, an increase of 11.2% over corresponding previous period
 - US formulation revenue stood at INR 1,738.8 Cr vs INR 1,643.2 Cr in Q4FY17, witnessed a growth of 5.8% YoY
 - Europe formulation revenue reported a strong growth of 48.2% to INR 1,151.6 Cr
 - ARV revenue at INR 148.6 Cr vs. INR 261.9 Cr in Q4FY17
 - Growth Markets revenue at INR 209.6, up 6.4% against Q4 last year
 - API revenue increased by 4.8% to INR 799.6 Cr

AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com

- EBIDTA before Forex and Other income at INR 804.0 Cr vs INR 721.2 Cr, a growth of 11.5% YoY; EBITDA margin at 19.9%
- Net Profit after JV share, minority interest at INR 528.5 Cr as against INR 532.5 Cr in the corresponding previous period.
- Basic & Diluted EPS is INR 9.02 per share.
- Research & Development (R&D) spend at INR 186.6 Cr, 4.6% of revenue
- Received final approval for 10 ANDAs from USFDA



Commenting on the Company's performance, Mr. N. Govindarajan, Managing Director of the company said: *"The company has reported a healthy growth in revenues and profitability in FY18, led by improvement in most of the markets. We continue to ramp up investment in differentiated and speciality product portfolio. Our execution strength and pipeline evolution will drive growth for the future."*

Operational Performance (Consolidated):



Gross Sales (Amt in INR Cr)	Q4 FY17-18	Q4 FY16-17	% Chg	FY17-18	FY16-17	% Chg
Formulations						
USA	1,738.8	1,643.2	5.8	7,442.1	6,827.2	9.0
Europe	1,151.6	777.2	48.2	4,354.4	3,277.1	32.9
Growth Markets	209.6	197.1	6.4	897.1	755.6	18.7
ARV	148.6	261.9	-43.3	839.6	1,185.4	-29.2
Total Formulations	3,248.6	2,879.4	12.8	13,533.2	12,045.4	12.4
Active Pharmaceuticals Ingredients (API)						
Betalactum	532.7	512.1	4.0	1,992.3	2,043.4	-2.5
Non Betalactum	266.9	250.6	6.5	969.9	998.6	-2.9
Total API	799.6	762.8	4.8	2,962.2	3,042.1	-2.6
Consolidated Gross Sales	4,048.3	3,642.2	11.2	16,495.4	15,087.5	9.3
Dossier Income	0.8	-0.6		4.4	2.4	
Revenue from operations	4,049.1	3,641.6	11.2	16,499.8	15,089.9	9.3

Consolidated Revenue breakup - Geography & segment wise

Q4FY18



FY18



Formulations

Formulation revenue for the year recorded a growth of 12.4% YoY to INR 13,533.2 Cr and accounted for 82% of total revenues. For the quarter, Formulation revenue registered a growth of 12.8% to INR 3,248.6 Cr

US Formulations

- In FY18, US revenue increased by INR 7,442.1 crore compared to INR 6,827.2 crore in FY17, accounting 45% of consolidated revenue. On constant currency basis, revenue grew by 13.4% to US\$ 1,156 million
- US revenue for Q4FY18 witnessed a growth of 5.8% YoY to INR 1,738.8 crore, accounting 43% of consolidated revenue. On constant currency basis, revenue grew by 10.1% YoY to US\$ 271 million
- Filed 11 ANDAs with USFDA including 2 injectables in Q4FY18 and 47 ANDAs including 16 injectables in FY18
- Received final approval for 10 ANDAs in Q4FY18 and 49 ANDAs including 7 injectables in FY18
- Launched 7 products including one injectable in Q4FY18 and 38 products including 6 injectables in FY18
- As on 31st Mar 2018, on a cumulative basis, the company filed 478 ANDAs with USFDA and received approval for 361 ANDAs including 34 tentative* approvals

*Tentative approvals include 11 ANDAs approved under PEPFAR.

EU Formulations

- EU revenue in FY18 posted a strong growth of 32.9% to INR 4,354.4 crore, accounting 26% of consolidated revenue. On constant currency basis, revenue grew by 29.3%
- EU revenue in Q4FY18 witnessed a robust growth of 48.2% YoY to INR 1,151.6 crore, accounting 28% of consolidated revenue. On constant currency basis, revenue grew by 33.7% YoY
- As on 31st Mar, 2018, we have transferred manufacturing of 83 products from Europe to India

AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com

ARV Formulations

- ARV business revenue for FY18 was at INR 839.6 Cr compared to INR 1,185.4 Cr in FY17 and accounted for 5% of revenue
- ARV business revenue for 4QFY18 was at INR 148.6 Cr Vs. INR 261.9 Cr in Q4FY17 and accounted for 4% of revenue.

Growth Markets Formulations

- Revenue from Growth markets formulations in FY18 posted a strong growth of 18.7% YoY to INR 897.1 Cr and accounted for ~6% of revenue
- Revenue from Growth markets formulations in Q4FY18 up by 6.4% YoY to INR 209.6 Cr and accounted for ~5% of revenue

API business

- The Active Pharmaceuticals Ingredients business contributed 18% to the total revenues and posted a revenue of INR 2,962.2 Cr in FY18.
- API business registered a growth of 4.8% to INR 799.6 Cr in Q4FY18
- The company filed one DMFs with USFDA during the quarter.

Global Regulatory Filings:

Filings	Q4 FY17-18	Cumulative Filings as on 31 st Mar 2018
ANDAs (including filings made from Aurobindo USA)	11	478
DMFs (net including filings made from AuroNext and AuroPeptide)	1	227
Formulations Dossiers in other key advanced markets (incl. Multiple registrations into Europe. South Africa and Canada)	78	3,400
API DMF/COS filings in other key regulated markets (incl. Multiple registrations)	51	2,748

AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com

USFDA approvals received in Q4 FY17-18:

Final Approvals

1	Abacavir Sulfate for Oral Sol. (gZiagen®) 20mg/ml	Anti-Retrovirals
2	Emtricitabine & Tenofovir Disoproxil Fumarate Tab, (gTruvada) 200 mg / 300 mg	Anti-Retrovirals
3	Tenofovir Disoproxil Fumarate Tab (gViread) 150mg, 200mg, 250mg and 300 mg	Anti-Retrovirals
4	Armodafinil Tab (gNuvigil) 50 mg, 150 mg and 250 mg	CNS
5	Cinacalcet Tab (gSensipar) 30 mg, 60 mg and 90 mg	Calcium Regulator
6	Sumatriptan and Naproxen Sodium Tab (gTreximet) 85 mg/500 mg	Pain Relief
7	Ibuprofen Oral Suspension 100 mg/5 mL	Pain Relief
8	Niacin Extended-Release Tab (gNiaspan) 500 mg, 750 mg and 1000 mg	CVS
9	Drospirenone and Ethinyl Estradiol Tab (gYaz) 3 mg/0.02 mg	Oral Contraceptive
10	Drospirenone and Ethinyl Estradiol Tab (gYasmin) 3 mg/0.03 mg	Oral Contraceptive

Earnings call details

The company will host an earnings call at 8.30 AM IST on May 29, 2018, to discuss the performance and answer any questions from participants.

Participants can dial-in on the numbers below

Primary Numbers: +91 22 6280 1292 / +91 22 7115 8193

Local Access Number: +91 70456 71221 (Available all over India)

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP:IN) headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, EU, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retroviral, CVS, CNS, Gastroenterological, Pain management and Anti-Allergic, supported by an outstanding R&D set-up. The Company is marketing these products globally in over 150 countries.

For further information, please contact:

Krishna Kiran

Investor Relations

Phone: 040-66725401 / 66725000

Mobile: +91 98486 67906

Email: ir@aurobindo.com

Disclaimer:

This press release contains statements that may constitute "forward looking statements" including and without limitation, statements relating to product characteristics and uses, sales potential and target dates for product launch, implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward looking statements represent our judgment and future expectations concerning the development of our business, a number of risks, uncertainties and other factors could cause actual developments and results to differ materially from our expectations. The company undertakes no obligation to publicly revise any forward looking statements to reflect future events or circumstances and will not be held liable for any use of this information.

AUROBINDO PHARMA LIMITED

(CIN : L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com

AUROBINDO PHARMA LIMITED
(CIN - L24239TG1986PLC015190)

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India

Tel: +91 040 23736370 ; Fax: +91 40 23747340 ; Email: info@aurobindo.com

(Rs. In lakhs)

STATEMENT OF CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31.03.2018					
Particulars	Quarter ended			Year ended	
	31.03.2018	31.12.2017	31.03.2017	31.03.2018	31.03.2017
	Audited	Unaudited	Audited	Audited	Audited
1 Revenue from operations					
(a) Net sales/ income from operations (refer note 4)	398,863	426,899	358,213	1,623,287	1,484,479
(b) Other operating income	6,046	6,712	5,950	26,697	24,507
Total revenue from operations	404,909	433,611	364,163	1,649,984	1,508,986
2 Other income					
(a) Foreign exchange gain (net)	-	726	1,903	-	6,205
(b) Others	4,383	2,579	2,175	10,198	5,384
Total other income	4,383	3,305	4,078	10,198	11,589
Total income (1+2)	409,292	436,916	368,241	1,660,182	1,520,575
3 Expenses					
(a) Cost of materials consumed	142,779	138,371	127,942	562,937	518,492
(b) Purchase of stock-in-trade	46,673	44,283	34,769	160,588	155,854
(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(22,505)	(904)	(12,430)	(48,251)	(30,920)
(d) Employee benefits expense	58,127	54,068	46,346	213,084	176,776
(e) Finance costs	2,472	1,886	1,428	7,771	6,672
(f) Foreign exchange loss (net)	1,592	-	-	1,676	-
(g) Depreciation and amortisation expense	15,663	13,808	10,005	55,797	42,763
(h) Other expenses	99,432	95,235	95,412	382,774	345,356
Total expenses	344,233	346,747	303,472	1,336,376	1,214,993
4 Profit before tax (1+2-3)	65,059	90,169	64,769	323,806	305,582
5 Share of profit of joint ventures, net of tax	56	11	168	314	502
6 Profit before tax (4+5)	65,115	90,180	64,937	324,120	306,084
7 Tax expense	12,239	30,694	11,715	81,828	75,964
8 Net profit for the period (6-7)	52,876	59,486	53,222	242,292	230,120
9 Non controlling interest	25	(15)	(23)	(26)	(47)
10 Net profit after taxes and non controlling interest (8-9)	52,851	59,501	53,245	242,318	230,167
11 Other Comprehensive income/ (expense)					
i) items that will not be reclassified subsequently to profit or loss (net of tax)	196	(137)	40	(237)	(579)
ii) items that will be reclassified subsequently to profit or loss	10,184	(4,729)	(10,269)	15,191	(8,044)
Total other comprehensive income	10,380	(4,866)	(10,229)	14,954	(8,623)
12 Total Comprehensive income for the period (10+11)	63,231	54,635	43,016	257,272	221,544
13 Paid-up equity share capital (face value Re. 1 per share)	5,859	5,859	5,859	5,859	5,859
14 Other equity				1,162,183	931,332
15 Earnings per equity share of Re. 1 each (not annualised)					
(a) Basic	9.02	10.16	9.10	41.36	39.33
(b) Diluted	9.02	10.16	9.10	41.36	39.33

AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad - 500 084 T.S., INDIA Tel: +91 40 6672 5000 / 1200 Fax: +91 40 6707 4059

Regd. Off.: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel: +91 40 2373 6370 Fax: +91 40 2374 7340, Email: info@aurobindo.com

www.aurobindo.com

NOTES:

- 1 The financial results of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder.
- 2 The above consolidated financial results have been prepared in accordance with principles and procedures as set out in the Ind AS 110 on "Consolidated financial statements" and Ind AS 28 on "Investments in Associates and Joint Ventures" notified under Section 133 of Companies Act, 2013 and Companies (Indian Accounting Standards) Rules, 2015, as amended.
- 3 The above consolidated financial results as reviewed by the audit committee have been approved by Board of Directors at its meeting held on May 28, 2018.
- 4 Post implementation of Goods and Services Tax ('GST') with effect from July 1, 2017, revenues from operations is disclosed net of GST. Revenue from operations for the earlier periods included excise duty which is now subsumed in the GST. Revenue from operations for the year ended March 31, 2018 includes excise duty upto June 30, 2017. Accordingly, revenue from operations for the quarter and year ended March 31, 2018 are not comparable with those of the previous periods presented.
- 5 During the year, Agile Pharma B.V., a step down subsidiary of the Company acquired Generis Farmacêutica SA and its subsidiaries viz. (i) Mer Medicamentos, Portugal (ii) Generis Phar Unipessoal Lda, Portugal (iii) Farma APS - Pmocado de Medicamentos, Unipessoal Lda., Portugal (iv) Generis Mozambique Lda, Mozambique. The above consolidated financial results for the current quarter and year ended March 31, 2018 includes the results of operations of the above entities from May 01, 2017. The corresponding figures for the previous periods are not comparable.
- 6 During the quarter i) Acrotech Biopharma LLC - Incorporated on January 5, 2018 ii) Aurovitas Pharma (Taizhou) Ltd - Incorporated on January 29, 2018. iii) Aurobindo Pharma USA LLC - (Dissolved w.e.f March 31, 2018). iv) Farma APS - Pmocado de Medicamentos, Unipessoal Lda., (Dissolved w.e.f. January 25, 2018). v) Generis Mozambique, Lda (Dissolved w.e.f March 19, 2018). vi) Mer Medicamentos, Lda (Merged with Generis Farmaceuita SA effective April 1, 2018). vii) Aurovitas, Unipessoal LDA (Merged with Generis Farmaceuita SA effective April 1, 2018). viii) Aurobindo Pharma (Portugal) Unipessoal Limitada (Merged with Generis Farmaceuita SA effective April 1, 2018).
- 7 The Company operates in only one segment viz., 'Pharmaceutical Products'.
- 8 The figures of the quarter ended March 31, 2018 and March 31, 2017 are the balancing figures between audited figures in respect of the full financial year upto March 31, 2018 and March 31, 2017 respectively and the unaudited published year to date figures upto December 31, 2017 and December 31, 2016 respectively, being the date of the end of the third quarter of the financial year. The consolidated results for the nine months ended December 31, 2017 and December 31, 2016 have been subjected to the limited review by the statutory auditors.
- 9 The Company has allotted 25,200 equity shares of Re.1/- (Rupee One only) on March 28, 2018 to the employees under Employee Stock option plan 2006. Consequent to the allotment, the paid-up share capital of Company has increased from 585,882,409 to 585,907,609 equity shares of Re.1/- each.
- 10 Previous period figures have been regrouped/rearranged wherever considered necessary to conform to the current period presentation.

By Order of the Board

Place: Hyderabad
Date : May 28, 2018

www.aurobindo.com

N.Govindarajan
Managing Director

AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off. : Plot No. 2, Maitrivihaar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com

Consolidated Balance Sheet

(Rs. In lakhs)

Consolidated Balance Sheet		(Rs. in lakhs)	
Sl. No.	PARTICULARS	As at	As at
		31.03.2018	31.03.2017
		(Audited)	(Audited)
	ASSETS		
1	Non-current assets		
	Property, plant and equipment	473,656	408,305
	Capital work-in-progress	139,954	123,736
	Goodwill	81,654	40,630
	Other intangible assets	96,757	34,443
	Intangible assets under development	18,350	22,072
	Financial assets		
	Investments	31,151	24,585
	Loans	544	570
	Other financial assets	8,746	7,517
	Non current tax assets (net)	8,259	5,798
	Deferred tax assets (net)	15,880	16,776
	Other non-current assets	16,783	19,892
	Non-Current assets	891,734	704,324
2	Current assets		
	Inventories	585,842	433,054
	Financial assets		
	Investments	2	2
	Trade receivables	308,436	276,533
	Cash and cash equivalents	121,590	48,944
	Bank balances other than above	4,572	2,404
	Loans	1,019	1,089
	Other financial assets	79,420	75,765
	Current tax assets (net)	6,455	1,751
	Other current assets	111,449	81,076
	Current assets	1,218,785	920,618
	TOTAL ASSETS	2,110,519	1,624,942
	EQUITY AND LIABILITIES		
1	Equity		
	Equity share capital	5,859	5,859
	Other equity	1,162,183	931,332
	Non-controlling interest	182	208
	Equity	1,168,224	937,399
	Liabilities		
2	Non-current liabilities		
	Financial liabilities		
	Borrowings	45,120	18,140
	Provisions	5,586	3,913
	Deferred tax liability (net)	23,528	4,930
	Non-current liabilities	74,234	26,983
3	Current liabilities		
	Financial liabilities		
	Borrowings	403,134	290,272
	Trade payables	262,743	215,470
	Other financial liabilities	51,000	46,938
	Other current liabilities	126,780	81,743
	Provisions	20,093	23,491
	Current tax liabilities	4,311	2,646
	Current liabilities	868,061	660,560
	TOTAL EQUITY AND LIABILITIES	2,110,519	1,624,942

AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com